http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2000512628-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7064 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 1997-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2000512628-A |
| titleOfInvention | Treatment of HIV infection by disrupting the interaction of host topoisomerase with HIV gag and RT |
| abstract | (57) [Summary]nThe present invention relates to therapeutic protocols and pharmaceutical compositions designed to target topo (I) for treating HIV infection. The present invention relates to therapeutic methods and pharmaceutical compositions for treating HIV infection using human topo (I) and the interaction of human topo (I) with HIV gag and RT as intervention targets. The invention further relates to the use of human topo (I) to increase the activity of RT. The present invention also relates to the expression of human topo (I) in transgenic animals (particularly mice) as a system for studying the HIV life cycle and screening for drugs for its ability to disrupt the HIV life cycle. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004023138-A1 |
| priorityDate | 1996-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 651.